IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
about
Childhood acute lymphoblastic leukemia: Integrating genomics into therapyChildren's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia.The clinical path to integrated genomics in ALL.Constitutive function of the Ikaros transcription factor in primary leukemia cells from pediatric newly diagnosed high-risk and relapsed B-precursor ALL patients.An advanced fragment analysis-based individualized subtype classification of pediatric acute lymphoblastic leukemia.CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.Function of Ikaros as a tumor suppressor in B cell acute lymphoblastic leukemiaIdentification of ETV6-RUNX1-like and DUX4-rearranged subtypes in paediatric B-cell precursor acute lymphoblastic leukaemia.What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.Absence of Genomic Ikaros/IKZF1 Deletions in Pediatric B-Precursor Acute Lymphoblastic Leukemia.Direct interaction of Ikaros and Foxp1 modulates expression of the G protein-coupled receptor G2A in B-lymphocytes and acute lymphoblastic leukemia.Copy number genome alterations are associated with treatment response and outcome in relapsed childhood ETV6/RUNX1-positive acute lymphoblastic leukemia.Risk factors for relapse in childhood acute lymphoblastic leukemia: prediction and prevention.Ikaros and leukaemia.Transcription factor networks in B-cell differentiation link development to acute lymphoid leukemia.Molecular profiling of gene copy number abnormalities in key regulatory genes in high-risk B-lineage acute lymphoblastic leukemia: frequency and their association with clinicopathological findings in Indian patients.Ikaros: Exploiting and targeting the hematopoietic stem cell niche in B-progenitor acute lymphoblastic leukemia.Genomic and transcriptional landscape of P2RY8-CRLF2-positive childhood acute lymphoblastic leukemia.Prognostic significance of cytokine receptor-like factor 2 alterations in acute lymphoblastic leukemia: a meta-analysis.Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: an international collaborative study.Selected miRNA levels are associated with IKZF1 microdeletions in pediatric acute lymphoblastic leukemia.IKZF1 deletion is an independent prognostic marker in childhood B-cell precursor acute lymphoblastic leukemia, and distinguishes patients benefiting from pulses during maintenance therapy: results of the EORTC Children's Leukemia Group study 58951.Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.Overexpression of lymphoid enhancer-binding factor-1 (LEF1) is a novel favorable prognostic factor in childhood acute lymphoblastic leukemia.Loss-of-function but not dominant-negative intragenic IKZF1 deletions are associated with an adverse prognosis in adult BCR-ABL-negative acute lymphoblastic leukemia.Expression profiling of adult acute lymphoblastic leukemia identifies a BCR-ABL1-like subgroup characterized by high non-response and relapse ratesIncidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia.Philadelphia chromosome-like acute lymphoblastic leukemia.An intragenic ERG deletion is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions.A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.ETV6-ABL1 fusion combined with monosomy 7 in childhood B-precursor acute lymphoblastic leukemia.Constitutional abnormalities of IDH1 combined with secondary mutations predispose a patient with Maffucci syndrome to acute lymphoblastic leukemia.The role of G protein-coupled receptors in lymphoid malignancies.Childhood acute lymphoblastic leukemia-associated risk-loci IKZF1, ARID5B and CEBPE and risk of pediatric non-Hodgkin lymphoma: a report from the Berlin-Frankfurt-Münster Study Group.ERG deletion is associated with CD2 and attenuates the negative impact of IKZF1 deletion in childhood acute lymphoblastic leukemia.miR expression profiling at diagnosis predicts relapse in pediatric precursor B-cell acute lymphoblastic leukemia.The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia.New biological and genetic classification and therapeutically relevant categories in childhood B-cell precursor acute lymphoblastic leukemia
P2860
Q28080463-89BE822B-4DCD-4823-A646-380525A3244AQ33711119-D8E3EB05-B074-4271-90EC-BC0B6A6DE6F4Q34106773-81A54768-76ED-4D65-B862-5965681FC3FBQ35053686-60EDE1A0-CE35-4D70-B263-BEC9BFDAE22AQ35869978-038FDF0E-8DA3-45BF-95C3-4276FBC836EFQ36115668-D3B35C64-F917-4AAC-A9CE-C277D9D78B74Q36154689-9C173767-9E7D-4E1C-8798-75FCFC037C12Q36562871-88B7F3B1-949A-4FFD-8C35-42B6D4542EF4Q36980511-92876AC8-7E84-4341-A5E4-29DB148B732EQ37060647-A7B41993-E511-4D12-A340-7523C54079B4Q37226741-22231040-F4DC-45CC-A599-633DE22E89D3Q37517874-ECE43754-17D7-4B7A-80B5-64A93FB58271Q37662338-3374F7E8-170A-41D2-AC04-DDA7E482181DQ37676290-DABEC941-3634-441D-874E-28F45C358203Q38264774-0C7BADCD-70BB-4985-9EA5-0F6F1DDB532DQ38371003-F14B2496-E10D-41DD-9A01-A700BDBDBCA7Q38492313-745D2523-25EE-4E74-B4A4-9C11AF528B86Q38841153-94FA4AD9-B9E8-42D5-9297-6D6B2479F5A6Q39014321-5201B85A-AFE3-46CE-91EE-C2E6D82EB4BEQ41000106-3005FF17-E9F3-4131-9AFC-5F16792CC9CAQ41003977-7640976E-6AE7-430C-A3B3-8D6C7C0156A8Q41556401-07ECFFA6-BBE0-4A46-9887-CE6DD038DC69Q41617996-B4016919-0BE3-4D8F-8876-6C59BAD0EC72Q41688725-12B0A1E1-2215-46C5-BFF2-D9F540B82CB7Q41697696-20C87FDC-8516-41D9-9158-00B642345DA6Q41752588-1FF4C9A9-CB3A-4043-80B0-7763BC6DCCF8Q42368324-1FD86D40-45E1-4A02-81E6-7D4347F566AAQ42384528-0AA5330B-8BCE-489A-B623-1151504A4482Q42831356-7745F0D5-4F43-407E-BF7D-565B1F832159Q43431904-FB83F836-95D3-48F6-958A-18BEFDDB67C2Q43922213-5EAF9F19-6C4F-433F-845B-6341BB1F4F30Q47203054-3C40698E-EFFD-4031-8897-355531172BC2Q47572594-CBBC0B6F-AAF3-4A2E-BA78-631B344801F8Q47752623-B93C7BD2-4558-45CD-A58B-CCB817544F74Q47960121-877D25D1-23A6-48FB-B9DA-B003F3F394F5Q52875595-2C51B047-9EF1-4623-9B90-FBF5F3A96513Q52882383-AAE947AF-0FCB-4BEB-A362-A2D8C89170BAQ53243813-1C885DFD-4CB4-4C33-9B67-6CAFD6E9FD19Q53703572-DA827CA1-1CFD-4099-9901-7F44F8194F54Q57821013-3DBB8973-5184-48E6-89DE-423740C8E7C6
P2860
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
IKZF1 deletion is an independe ...... to the ALL-BFM 2000 protocol.
@en
type
label
IKZF1 deletion is an independe ...... to the ALL-BFM 2000 protocol.
@en
prefLabel
IKZF1 deletion is an independe ...... to the ALL-BFM 2000 protocol.
@en
P2093
P2860
P1433
P1476
IKZF1 deletion is an independe ...... to the ALL-BFM 2000 protocol.
@en
P2093
Andrea Teigler-Schlegel
André Schrauder
Anja Möricke
Barbara Meissner
Claus R Bartram
Denis Schewe
Gunnar Cario
Jean-Pierre Bouquin
Jochen Harbott
Martin Zimmermann
P2860
P304
P356
10.3324/HAEMATOL.2011.056135
P577
2012-08-08T00:00:00Z